Navigation Links
Immunosyn Corporation Files 10-Q
Date:5/16/2008

LA JOLLA, Calif., May 16 /PRNewswire-FirstCall/ -- Immunosyn Corporation (OTC Bulletin Board: IMYN), a biotechnology firm that has obtained exclusive worldwide marketing, sales and distribution rights to the biopharmaceutical SF-1019 from its affiliate Argyll Biotechnologies, LLC, has announced its results for the quarter ending March 31, 2008.

For the quarter ended March 31, 2008, the company incurred $175,632.00 in general and administrative expenses and $13,393.00 in interest expense which was funded from advances by affiliates of $179,798.00, accounts payable of $32,249.00 and accrued expenses of $12,151.00. As a result, the company had a Net Loss of $189,025.00 for the first quarter of 2008. During the same period in 2007, the company incurred $162,714.00 in general and administrative expenses and interest expense of $3,714.00 and had a Net Loss of $166,428.00. Immunosyn has had no revenue to date as Argyll Biotechnologies, LLC is still in the process of obtaining governmental and regulatory approval for SF-1019.

"We have continued to significantly control costs this quarter and appreciated the advances from affiliates," noted Stephen Ferrone, Immunosyn's CEO. "In 2008, Argyll Biotechnologies, LLC has reported positive research results for SF-1019 and Immunosyn hopes to add shareholder value by striving for financial efficiency in the execution of its marketing and distribution strategy when approvals for SF-1019 are obtained by Argyll Biotechnologies, LLC," added Ferrone.

Research suggests that SF-1019 has analgesic properties with a perceived ability to substantially reduce the inflammation present in a number of clinical conditions including Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Reflex Sympathetic Dystrophy Syndrome, (RSD or RSDS) and other auto-immune and neurological disorders. A limited proof of concept trial for SF-1019 in Europe has shown positive results in effectively treating di
'/>"/>

SOURCE Immunosyn Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Immunosyn Corporation Announces 2007 Results, Files 10KSB
2. USANAs CEO Myron W. Wentz, Ph.D. Has Been Elected to Serve on Immunosyn Corporations Board of Directors
3. Immunosyn Announces Interview of CEO Stephen D. Ferrone by CEOCFO Interviews & News
4. WallSt.net Announces Upcoming Interview With CEO Of Immunosyn Corporation
5. Immunosyn Corporation Names G. David Criner as CFO
6. Immunosyn Corporation to Present at FSX
7. CorVel Corporation Announces Earnings Release Webcast
8. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
9. Baxa Corporation Wins Two Colorado BMA 2008 Gold Key Awards
10. Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
11. Triple-S Management Corporation Appoints New Non-Executive Chairman to Board; Adds New Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... miRagen Therapeutics, Inc., a biopharmaceutical company focused on ... for cardiovascular and muscle disease, today announced the ... a crucial role in the progression of amyotrophic ... in neuromuscular synaptic regeneration in mice. The ... the journal Science , reveal miR-206 as ...
(Date:12/11/2009)... Boston College researchers have observed the "hot electron" effect ... successfully harvested the elusive charges using ultra-thin solar cells, ... the authors report in the current online edition of ... captured in solar cells, it generates free electrons in ... snare these charges, the electrons must reach the bottom ...
(Date:12/11/2009)... 11 Algeta ASA (OSE: ALGETA), ... clinical center in the,US, the Tulane Cancer ... the phase III clinical study of Alpharadin ... prostate cancer,(CRPC) that has metastasized to the ... ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) study ...
(Date:12/11/2009)... Gwathmey, Inc., a pre-clinical contract research ... aureus, and cardiovascular disease announces a new CEO. ... Rosalie Dunn, Ph.D., has joined Gwathmey as Chief ... years of experience working with small businesses and ... Dr. Dunn managed multimillion dollar portfolios for the ...
Breaking Biology Technology:miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Elusive 'hot' electrons captured in ultra-thin solar cells 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer 2
... William C Heiser, PhD and Ma Theresa Redila-Flores, Bio-Rad Laboratories, , ... , ... assessment of viable cell number and proliferation , ... are necessary and useful for analysis of growth factor activity, ...
... by G.H. Goldman, R. Geremia, M. Van,Montagu, and A. Herrera-Estrella, Laboratorium voor,Genetica, Rijksuniversiteit ... Introduction , ... , a high concentration of polyethylene ... period of exposure to DNA. However, electroporation could also be useful , ...
... Maren Bell and Robert Mortimer, Human Genome Center, Division,of Cell and Molecular ... , Introduction , ... chromosomes (YACs) has traditionally , been ... is complicated, often unreliable, and transformation efficiencies are ...
Other Biology Technology:Cell Proliferation Assay Using the Benchmark Plus Microplate Spectrophotometer 2Cell Proliferation Assay Using the Benchmark Plus Microplate Spectrophotometer 3Transformation of Filamentous Fungi by High-Voltage Electroporation 2Transformation of Filamentous Fungi by High-Voltage Electroporation 3Transformation of Filamentous Fungi by High-Voltage Electroporation 4Transformation of Filamentous Fungi by High-Voltage Electroporation 5Transformation of Filamentous Fungi by High-Voltage Electroporation 6Transformation of Filamentous Fungi by High-Voltage Electroporation 7Transformation of Filamentous Fungi by High-Voltage Electroporation 8Electroporation of Yeast Artificial Chromosomes 2Electroporation of Yeast Artificial Chromosomes 3Electroporation of Yeast Artificial Chromosomes 4
(Date:12/11/2009)... and initiate different survival strategies say they have gained ... affect their health, wealth and the fate of others ... the early online edition of the journal Proceedings ... when the scientists applied the mathematical techniques used in ... proteins that colonies of bacteria rely upon to initiate ...
(Date:12/11/2009)... nearly two decades, Ivy Pike, an associate professor of ... ethnic groups in rural northern Kenya to understand how ... living there. , The results of her and her ... in three pastoralist communities of northern Kenya: A conceptual ... Social Science and Medicine , in collaboration with ...
(Date:12/11/2009)... Arno Motulsky, the senior editor of the 4th edition ... Human Genetics, was recently given the Victor A. McKusick ... contributions to the field of human genetics, was presented ... American Society of Human Genetics on 24 October 2009 ... Medicine and Genome Sciences at the University of Washington ...
Breaking Biology News(10 mins):Bacteria provide new insights into human decision making 2Bacteria provide new insights into human decision making 3Bacteria provide new insights into human decision making 4Bacteria provide new insights into human decision making 5UA-led study grapples with health effects of low-intensity warfare 2Bad Air Day Alert 3A Outdoor Air Pollutants at High Level 54653 1Bad Air Day Alert 3A Outdoor Air Pollutants at High Level 54653 2Bad Air Day Alert 3A Outdoor Air Pollutants at High Level 54653 3Developmental language disorders at preschool age 3A no proof of benefit from screening 54648 1Developmental language disorders at preschool age 3A no proof of benefit from screening 54648 2Developmental language disorders at preschool age 3A no proof of benefit from screening 54648 3Study supports DNA repair blocker research in cancer therapy 9597 1Study supports DNA repair blocker research in cancer therapy 9597 2Study supports DNA repair blocker research in cancer therapy 9597 3
... a lot of negative health news, but in the July ... rats suggests that trans-fats do not increase the risk of ... area of concern. , Epidemiological studies indicate that chronic ... unusual molecular shapes can reduce muscle,s ability to burn energy; ...
... July 8, 2008) A new partnership between the ... Development (ORD) and the Gund Institute for Ecological Economics ... more accurately determine the costs and benefits of actions ... of nature such as clean air and water, erosion ...
... In a collaborative project scientists from the Max-Planck-Institute for ... with a business in Munich, Germany and Ann Arbor, ... to generate an unprecedented view at the human transcriptome. ... lines revealed so far unrecognized complexity and variability of ...
Other Biology News:US EPA, UVM's Gund Institute team up to develop new ways to understand ecosystem services 2Deep sequencing study reveals new insights into human transcriptome 2
... Shakers have the durability to ... 3-high, and the uniformity and ... shake" applications. Heavily built ... our stackers are designed for ...
Dedicated 29.5" X 18" platforms for Stackable shakers. These platforms are optimized for a particular flask clip size and are sold with a full load of flask clips....
... Orbital Shakers combine high durability and ... power. The patented triple-counterbalanced heavy-duty ... to run with heavy out-of-balance loads. ... reduces contamination. The heavy stainless ...
... Electroporator is a simple, easy to ... in bacterial and yeast applications. ... two voltages and either one mm, ... On pressing the pulse button the ...
Biology Products: